Antibodies against human csf-1r and uses thereof

Abstract

The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

1 - 16 . (canceled) 
     
     
         17 . A method for treating a patient suffering from cancer associated with macrophage colony-stimulating factor 1 receptor (CSF-1R) expression, the method comprising administering to the patient an effective amount of an isolated antibody binding to human CSF-1R, or an antibody fragment thereof,
 wherein the antibody comprises a heavy chain variable domain comprising a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2, and a CDR1 region of SEQ ID NO:3, and a light chain variable domain comprising a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO:5, and a CDR1 region of SEQ ID NO:6.   
     
     
         18 . A method for treating a patient suffering from bone loss associated with CSF-1R expression, the method comprising administering to the patient an effective amount of an isolated antibody binding to human CSF-1R, or an antibody fragment thereof,
 wherein the antibody comprises a heavy chain variable domain comprising a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2, and a CDR1 region of SEQ ID NO:3, and a light chain variable domain comprising a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO:5, and a CDR1 region of SEQ ID NO:6.   
     
     
         19 . A method for treating a patient suffering from metastasis associated with CSF-1R expression, the method comprising administering to the patient an effective amount of an isolated antibody binding to human CSF-1R, or an antibody fragment thereof,
 wherein the antibody comprises a heavy chain variable domain comprising a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2, and a CDR1 region of SEQ ID NO:3, and a light chain variable domain comprising a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO:5, and a CDR1 region of SEQ ID NO:6.   
     
     
         20 . A method for treating a patient suffering from inflammatory diseases associated with CSF-1R expression, the method comprising administering to the patient an effective amount of an isolated antibody binding to human CSF-1R, or an antibody fragment thereof,
 wherein the antibody comprises a heavy chain variable domain comprising a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2, and a CDR1 region of SEQ ID NO:3, and a light chain variable domain comprising a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO:5, and a CDR1 region of SEQ ID NO:6.   
     
     
         21 . The method of  claim 17 , wherein the antibody, or antibody fragment thereof, of claim  1 , wherein the antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 7, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:8. 
     
     
         22 . The method of  claim 17 , wherein the antibody, or antibody fragment thereof, is capable of binding human CSF-1R with a Kd value of 1 nM or lower. 
     
     
         23 . The method of  claim 17 , wherein the antibody, or antibody fragment thereof, inhibits human CSF-1 binding to CSF-1R with an IC50 value of 25 ng/ml or lower. 
     
     
         24 . The method of  claim 17 , wherein the antibody, or antibody fragment thereof, is human IgG1 subclass or is of human IgG4 subclass. 
     
     
         25 . The method of  claim 17 , wherein the antibody, or antibody fragment thereof, is a CDR grafted, humanized, T cell epitope depleted, chimeric, single chain, or multispecific antibody 
     
     
         26 . The method of  claim 17 , wherein the antibody, or antibody fragment thereof, is a monoclonal antibody. 
     
     
         27 . The method of  claim 17 , wherein the antibody, or antibody fragment thereof, is conjugated to a cytotoxic agent. 
     
     
         28 . The method of  claim 27 , wherein the cytotoxic agent is a chemotherapeutic agent, a growth inhibitory agent, a toxin, or a radioactive isotope.